FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039836717> ?p ?o ?g. }

• W2039836717 endingPage "1132" @default.
• W2039836717 startingPage "1123" @default.
• W2039836717 abstract "Background: Hepatic adverse events associated with the use of nonaspirin drugs and NSAIDs are uncommon, but the widespread use of these drugs may impact public health. Objective: We conducted a case/noncase analysis of spontaneous reports to compare the hepatic safety profile of cyclooxygenase (COX)-2 selective inhibitors with that of nonselective NSAIDs. Methods: This case/noncase analysis was conducted using the US Food and Drug Administration Freedom of Information (FDA/FOI) database (through quarter 1, 2003) and the World Health Organization Uppsala Monitoring Centre (WHO/UMC) database (through quarter 3, 2003). Council for International Organizations of Medical Sciences and WHO Adverse Reaction Terminology preferred terms were used to classify hepatic disorders with broad and specific case definitions. After reports involving established hepatotoxic drugs (bromfenac, nimesulide, sulindac) were excluded, the proportion of reports (PRs) of each case definition was calculated for each NSAID. Crude and adjusted reporting odds ratios (RORs) were used to compare the overall proportions of hepatic disorders and hepatic failure of celecoxib and rofecoxib versus nonselective NSAIDs. Results: A total of 158,539 and 185,253 reports of NSAIDs were identified in the FDA/FOI and WHO/UMC databases and 25% and 16%, respectively, involved other hepatotoxic drugs. The PRs of hepatic disorders for all COX-2 selective inhibitors and non-selective NSAIDs were 3.0% in the FDA/FOI database and 2.7% in the WHO/UMC database. In the FDA/FOI and WHO/UMC databases, respectively, mmesulide (16.7% and 14.4%), bromfenac (12.0% and 20.7%), diclofenac (8.1% and 4.7%), and sulindac (6.1 % and 9.9%) were reported to be associated with higher proportions of overall hepatic disorders compared with those of other NSAIDs. Crude and adjusted RORs for the prevalences of overall hepatic disorders and hepatic failure with celecoxib and rofecoxib versus the other NSAIDs were <1 (indicating that the proportion was not higher than that of the comparator) in both databases. The interpretation of the results was unchanged when bromfenac, nimesulide, and sulindac were excluded from the analysis. Conclusions: In this case/noncase analysis, bromfenac, nimesulide, sulindac, and diclofenac had higher proportions of reports of hepatic disorders compared with those of other NSAIDs in the FDA/FOI and WHO/UMC databases. The analysis did not raise a safety concern for celecoxib or rofecoxib versus NSAIDs for overall hepatic disorders and hepatic failure." @default.
• W2039836717 created "2016-06-24" @default.
• W2039836717 creator A5008677543 @default.
• W2039836717 creator A5025500200 @default.
• W2039836717 creator A5086526085 @default.
• W2039836717 creator A5088053431 @default.
• W2039836717 date "2006-08-01" @default.
• W2039836717 modified "2023-10-16" @default.
• W2039836717 title "Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: A case/noncase analysis of spontaneous reports" @default.
• W2039836717 cites W146098013 @default.
• W2039836717 cites W1621870792 @default.
• W2039836717 cites W1963646511 @default.
• W2039836717 cites W1971692835 @default.
• W2039836717 cites W1976185410 @default.
• W2039836717 cites W1977411240 @default.
• W2039836717 cites W1988386828 @default.
• W2039836717 cites W1997435071 @default.
• W2039836717 cites W1997798681 @default.
• W2039836717 cites W1998416434 @default.
• W2039836717 cites W2015544462 @default.
• W2039836717 cites W2020948173 @default.
• W2039836717 cites W2029709759 @default.
• W2039836717 cites W2034091859 @default.
• W2039836717 cites W2043371806 @default.
• W2039836717 cites W2057456214 @default.
• W2039836717 cites W2061720008 @default.
• W2039836717 cites W2064716383 @default.
• W2039836717 cites W2070610929 @default.
• W2039836717 cites W2072308065 @default.
• W2039836717 cites W2074493159 @default.
• W2039836717 cites W2091106636 @default.
• W2039836717 cites W2120553600 @default.
• W2039836717 cites W2131647146 @default.
• W2039836717 cites W2141299706 @default.
• W2039836717 cites W2150833176 @default.
• W2039836717 cites W2158299492 @default.
• W2039836717 cites W4246558036 @default.
• W2039836717 doi "https://doi.org/10.1016/j.clinthera.2006.08.014" @default.
• W2039836717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16982289" @default.
• W2039836717 hasPublicationYear "2006" @default.
• W2039836717 type Work @default.
• W2039836717 sameAs 2039836717 @default.
• W2039836717 citedByCount "30" @default.
• W2039836717 countsByYear W20398367172012 @default.
• W2039836717 countsByYear W20398367172013 @default.
• W2039836717 countsByYear W20398367172014 @default.
• W2039836717 countsByYear W20398367172015 @default.
• W2039836717 countsByYear W20398367172016 @default.
• W2039836717 countsByYear W20398367172017 @default.
• W2039836717 countsByYear W20398367172018 @default.
• W2039836717 countsByYear W20398367172019 @default.
• W2039836717 countsByYear W20398367172021 @default.
• W2039836717 countsByYear W20398367172022 @default.
• W2039836717 crossrefType "journal-article" @default.
• W2039836717 hasAuthorship W2039836717A5008677543 @default.
• W2039836717 hasAuthorship W2039836717A5025500200 @default.
• W2039836717 hasAuthorship W2039836717A5086526085 @default.
• W2039836717 hasAuthorship W2039836717A5088053431 @default.
• W2039836717 hasConcept C126322002 @default.
• W2039836717 hasConcept C156957248 @default.
• W2039836717 hasConcept C181199279 @default.
• W2039836717 hasConcept C185592680 @default.
• W2039836717 hasConcept C197934379 @default.
• W2039836717 hasConcept C199475168 @default.
• W2039836717 hasConcept C2776241388 @default.
• W2039836717 hasConcept C2776467144 @default.
• W2039836717 hasConcept C2777570176 @default.
• W2039836717 hasConcept C2778484676 @default.
• W2039836717 hasConcept C2778582115 @default.
• W2039836717 hasConcept C2779689624 @default.
• W2039836717 hasConcept C2779826273 @default.
• W2039836717 hasConcept C2780035454 @default.
• W2039836717 hasConcept C41008148 @default.
• W2039836717 hasConcept C55493867 @default.
• W2039836717 hasConcept C57658597 @default.
• W2039836717 hasConcept C71924100 @default.
• W2039836717 hasConcept C77088390 @default.
• W2039836717 hasConcept C98274493 @default.
• W2039836717 hasConceptScore W2039836717C126322002 @default.
• W2039836717 hasConceptScore W2039836717C156957248 @default.
• W2039836717 hasConceptScore W2039836717C181199279 @default.
• W2039836717 hasConceptScore W2039836717C185592680 @default.
• W2039836717 hasConceptScore W2039836717C197934379 @default.
• W2039836717 hasConceptScore W2039836717C199475168 @default.
• W2039836717 hasConceptScore W2039836717C2776241388 @default.
• W2039836717 hasConceptScore W2039836717C2776467144 @default.
• W2039836717 hasConceptScore W2039836717C2777570176 @default.
• W2039836717 hasConceptScore W2039836717C2778484676 @default.
• W2039836717 hasConceptScore W2039836717C2778582115 @default.
• W2039836717 hasConceptScore W2039836717C2779689624 @default.
• W2039836717 hasConceptScore W2039836717C2779826273 @default.
• W2039836717 hasConceptScore W2039836717C2780035454 @default.
• W2039836717 hasConceptScore W2039836717C41008148 @default.
• W2039836717 hasConceptScore W2039836717C55493867 @default.
• W2039836717 hasConceptScore W2039836717C57658597 @default.
• W2039836717 hasConceptScore W2039836717C71924100 @default.
• W2039836717 hasConceptScore W2039836717C77088390 @default.
• W2039836717 hasConceptScore W2039836717C98274493 @default.

• next